Incheon, South Korea – July 25, 2026 – South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics is executing an audacious global expansion strategy, cementing its position as a dominant force in the biopharmaceutical industry. A series of high-profile acquisitions and significant domestic investments underscore the company’s ambition to diversify its technological capabilities, extend its geographical footprint, and meet the burgeoning global demand for advanced biologics manufacturing.
n
The latest and most substantial move, announced on July 20, 2026, is Samsung’s intent to acquire PolyPeptide Group for a staggering $1.8 billion (SFr1.46 billion). This landmark deal, expected to close before the end of 2026, is poised to catapult Samsung Biologics into the rapidly expanding market of peptide-based active pharmaceutical ingredients (APIs), including the highly sought-after GLP-1 agonists. This follows closely on the heels of another pivotal transaction completed on March 31, 2026: the $280 million acquisition of GSK’s manufacturing facility in Rockville, Maryland, marking Samsung’s crucial entry into the lucrative U.S. market.
n
These strategic maneuvers are not merely about increasing capacity; they represent a calculated pivot towards comprehensive, end-to-end biomanufacturing solutions across diverse modalities and geographies. With a robust financial performance – achieving revenues of $3.1 billion (Won4,557 billion) in 2025, a 30% increase from the previous year – Samsung Biologics is leveraging its formidable growth trajectory to reshape the global CDMO landscape.
n
A Decade of Accelerated Growth and Strategic Milestones
n
Samsung Biologics’ ascent has been nothing short of meteoric since its inception. The company received its first license to produce biologic drug substances in 2015, a foundational milestone that paved the way for rapid expansion. This initial FDA approval was swiftly followed in 2016 by a Certificate of Good Manufacturing Practice (GMP) compliance from the European Medicines Agency (EMA) for biologics drug substance and drug product. Today, the company boasts over 450 approvals from regulatory bodies worldwide, a testament to its unwavering commitment to quality and compliance.
n
This impressive regulatory track record has been mirrored by consistent financial and operational growth. From its base in the Songdo Bio Cluster in Incheon, South Korea, Samsung Biologics has systematically expanded its manufacturing infrastructure. The Songdo cluster, already a hub of innovation, is set to become even more central to the company’s future. Samsung has recently acquired land for Bio Campus III, a dedicated site earmarked for future modalities such as cell and gene therapies and vaccines – areas critical for the next generation of biopharmaceuticals. Complementing this, an open innovation centre, built in partnership with Lilly Gateway Labs, is slated to open in 2027 within the cluster, designed to foster collaborative research and accelerate drug development.
n
However, the vision for sustained growth clearly extends beyond its South Korean strongholds. Recognizing the strategic imperative of global diversification, Samsung Biologics has meticulously planned its international expansion, culminating in the recent high-impact acquisitions.
n
The PolyPeptide Group Acquisition: A Leap into Peptide Therapeutics
n
The $1.8 billion acquisition of PolyPeptide Group represents a significant leap for Samsung Biologics, extending its capabilities beyond its established expertise in antibodies and antibody-drug conjugates (ADCs) into the burgeoning field of peptide therapeutics. PolyPeptide Group is a recognized leader in its niche, specializing in peptide-based APIs and reportedly producing one-third of the commercially approved peptides globally.
n
This acquisition is particularly timely given the explosion in demand for GLP-1 receptor agonists, a class of peptides revolutionizing the treatment of diabetes and obesity. By integrating PolyPeptide’s specialized knowledge and manufacturing prowess, Samsung Biologics is poised to become a key player in this high-growth segment. The deal not only brings critical technological expertise but also a formidable global network of manufacturing sites spanning Sweden, Belgium, France, the United States, and India. This geographical spread is further enhanced by a corporate office in Switzerland and an innovation centre in Strasbourg, France, providing Samsung Biologics with a truly international operational footprint for peptide manufacturing.
n
The strategic rationale is multifaceted:
n
- n
- Technological Diversification: Broadens Samsung’s offering from large molecule biologics (mAbs, ADCs) to include small molecule peptides, catering to a wider range of biopharmaceutical clients.
- Market Access: Immediately positions Samsung Biologics in the high-demand peptide market, particularly for GLP-1s, where manufacturing capacity is a critical bottleneck.
- Geographic Expansion: Leverages PolyPeptide’s existing global network to establish a manufacturing presence in key European and Indian markets, complementing Samsung’s recent U.S. entry.
- Innovation Synergy: Integrates PolyPeptide’s innovation capabilities to enhance R&D in peptide synthesis and development.
n
n
n
n
n
Establishing a U.S. Foothold with the GSK Rockville Facility
n
Prior to the PolyPeptide announcement, Samsung Biologics made its decisive entry into the U.S. market by acquiring GSK’s Rockville, Maryland facility. The $280 million transaction, completed on March 31, 2026, marked Samsung’s first manufacturing presence in the United States. This acquisition immediately added 60,000 liters of drug substance capacity, boosting Samsung’s global manufacturing capacity to an impressive 845,000 liters.
n
The U.S. market holds immense strategic importance for Samsung Biologics. As James Choi, Executive Vice President, Chief Marketing Officer, and Head of Sales Support, Project Management, and Global Public Affairs, elaborated in an interview with Pharmaceutical Technology at the 2026 BIO International Convention (BIO 2026) in San Diego, California, in June 2026: “Geographically, we’ve always been looking at expanding, starting with the US, because about half of our clients are US-based.”
n
Choi emphasized that this expansion was a long-term strategic endeavor, not merely a reaction to recent U.S. political pressures advocating for the onshoring of pharmaceutical manufacturing that intensified throughout 2025 and 2026. “It began many, many years before that and we looked at other plants, existing plants, we looked at greenfield opportunities, different locations, different biotech corridors, where we could build out and scale out,” Choi explained.
n
The Rockville site proved to be the ideal fit, ticking all critical boxes:
n
- n
- Strategic Location: Situated within an established biotech hub, offering access to a highly skilled talent pool and a robust biotechnology ecosystem.
- Talent Acquisition: The acquisition included approximately 500 seasoned GSK employees with extensive expertise in biomanufacturing, particularly in monoclonal antibodies (mAbs), aligning perfectly with Samsung’s core capabilities.
- Client Relationship: Acquiring the facility from GSK, a key client, ensures a smooth transition and continuity. GSK will continue to benefit from the site as Samsung supplies the products previously manufactured there, while Samsung simultaneously expands its services to additional contract manufacturing clients.
n
n
n
n
Future-Proofing the Rockville Operations: Expansion and Integration
n
Samsung Biologics has ambitious plans for its new U.S. facility in Rockville, Maryland. The site already possesses the capability to support clinical and commercial biologics production across multiple manufacturing scales, leveraging its two cGMP manufacturing plants. The company is committed to enhancing these capabilities and strengthening its long-term operational footprint in the region.
n
A cornerstone of Samsung’s integration strategy is its proprietary approach, termed ‘ExellenS’. This methodology aims to ensure seamless plant-to-plant processes and equipment equivalency across its global campuses. By standardizing operations and technologies, Samsung seeks to expedite regulatory approvals and streamline tech transfers, providing clients with unparalleled efficiency and consistency regardless of the manufacturing location.
“We do know that the site has potential to add more bioreactors,” Choi confirmed, outlining the ongoing assessment of the facility. “We’re looking at the different configurations, additional equipment that we would add or, in some cases, maybe even replace to allow the site to be more up to date, and also that equivalency with our existing campus in South Korea, so that it’s seamless in terms of process transfers and stuff like that.” This forward-looking approach underscores Samsung’s commitment to making Rockville a state-of-the-art facility capable of meeting future demands.
The Imperative of Manufacturing and Supply Chain Diversity
Samsung Biologics’ aggressive global expansion aligns perfectly with a broader industry trend towards greater supply chain resilience and geographical diversification. The acquisition of the GSK site provided its first U.S. facility, but the PolyPeptide deal will rapidly expand its global reach across Europe and India, addressing the growing imperative for regionalized manufacturing capabilities.
Governments worldwide, acutely aware of the vulnerabilities exposed during recent global crises, are actively promoting domestic biopharma manufacturing. The U.S. push for onshoring is complemented by similar initiatives in Europe. The EU’s Critical Medicines Act, finalized in January 2026, explicitly aims to boost the region’s production of APIs and essential drugs, reducing reliance on external supply chains.
James Choi articulated Samsung Biologics’ strategic philosophy on this critical issue: “There’s always going to be a balance when it comes to where production takes place. Nobody fully puts all their eggs in one basket. You’re always going to want to diversify your supply chain to reduce risk, so clients will always have a need for a secondary supply for that diversification of the risk portfolio, especially for their flagship products.”
He concluded with a definitive statement on the enduring wisdom of this approach: “Time and time again, geographic diversification has proven to be a sound business decision.” This principle is now a cornerstone of Samsung Biologics’ overarching strategy, designed to offer clients robust, resilient, and geographically diverse manufacturing solutions.
Implications and Future Outlook
Samsung Biologics’ strategic moves signal a transformative period for the company and the broader CDMO sector. By expanding into new modalities like peptides and cell & gene therapies, while simultaneously establishing a robust global manufacturing footprint, Samsung is positioning itself as an indispensable partner for pharmaceutical innovators worldwide.
The implications are profound:
- Enhanced Competitiveness: Samsung Biologics will offer a more comprehensive portfolio of services, from large molecule biologics to small molecule peptides, making it a more attractive partner for diverse biopharma companies.
- Risk Mitigation for Clients: The diversified manufacturing network across multiple continents provides clients with greater supply chain security, a critical factor in today’s volatile geopolitical and economic landscape.
- Leadership in Emerging Modalities: Investments in Bio Campus III and the PolyPeptide acquisition demonstrate a clear commitment to leading in next-generation therapies, including cell and gene therapies, vaccines, and peptide-based drugs.
- Talent and Innovation Hubs: The strategic locations in established biotech corridors and the acquisition of skilled workforces strengthen Samsung’s intellectual capital and innovative capacity.
As the biopharmaceutical industry continues its rapid evolution, driven by scientific breakthroughs and increasing global health demands, the role of advanced CDMOs like Samsung Biologics becomes ever more critical. The company’s calculated and aggressive expansion strategy not only underscores its ambition to be the world’s leading biomanufacturing partner but also reflects a keen understanding of the shifting dynamics of global drug development and supply chain resilience. With its burgeoning global empire, Samsung Biologics is poised to significantly influence the future of medicine.
